{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:50:15Z","timestamp":1794279015649,"version":"4.9.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.semarthrit.2024.152507","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T17:30:58Z","timestamp":1719941458000},"page":"152507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Modelling long-term outcomes for patients with systemic lupus erythematosus"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-2076","authenticated-orcid":false,"given":"Z.","family":"Touma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kayaniyil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Parackal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.D.","family":"Hille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ohsfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2410-4424","authenticated-orcid":false,"given":"S.","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.semarthrit.2024.152507_bib0001","first-page":"284","article-title":"Systemic lupus erythematosus: primary care approach to diagnosis and management","volume":"94","author":"Lam","year":"2016","journal-title":"Am Fam Physician"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152507_bib0002","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0961203318817132","article-title":"Disease course patterns in systemic lupus erythematosus","volume":"28","author":"Tselios","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2024.152507_bib0003","article-title":"Unfavourable Outcomes Associated with Glucocorticoid Use in Current Standard of Care Management of Systemic Lupus Erythematosus in Canada","author":"Touma","year":"2023","journal-title":"TBD"},{"issue":"7","key":"10.1016\/j.semarthrit.2024.152507_bib0004","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/0961203315627202","article-title":"Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis","volume":"25","author":"Lee","year":"2016","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152507_bib0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152507_bib0006","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3899\/jrheum.190259","article-title":"Effect of disease activity on organ damage progression in systemic lupus erythematosus: university of toronto lupus clinic cohort","volume":"48","author":"Urowitz","year":"2021","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152507_bib0007","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152507_bib0008","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152507_bib0009","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"10.1016\/j.semarthrit.2024.152507_bib0010","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152507_bib0011","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2165\/00019053-200017050-00004","article-title":"Modelling in health economic evaluation. What is its place? What is its value?","volume":"17","author":"Brennan","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152507_bib0012","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a Fifty-Two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152507_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025687","article-title":"Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol","volume":"9","author":"Teng","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152507_bib0014","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase iii randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.semarthrit.2024.152507_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","author":"van Vollenhoven","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2024.152507_bib0016","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","article-title":"A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS) Outcomes Model (UKPDS no. 68)","volume":"47","author":"Clarke","year":"2004","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152507_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000237","article-title":"Quantifying the burden of steroid-related damage in SLE in the Hopkins lupus cohort","volume":"5","author":"Davidson","year":"2018","journal-title":"Lupus Sci Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152507_bib0018","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/rheumatology\/keu375","article-title":"An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort","volume":"54","author":"Watson","year":"2015","journal-title":"Rheumatol Oxf Engl"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152507_bib0019","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.rdc.2005.01.008","article-title":"Contributions of observational cohort studies in systemic lupus erythematosus: the university of Toronto lupus clinic experience","volume":"31","author":"Urowitz","year":"2005","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152507_bib0020","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152507_bib0021","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152507_bib0022","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.semarthrit.2013.05.003","article-title":"The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review","volume":"43","author":"Sutton","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152507_bib0023","series-title":"Model selection and multimodel inference: a practical information-theoretic approach [Internet]","first-page":"49","article-title":"Information and likelihood theory: a basis for model selection and inference","author":"Burnham","year":"2002"},{"key":"10.1016\/j.semarthrit.2024.152507_bib0024","series-title":"The use of health economic methods in the development of new interventions for systemic lupus erythematosus [Internet] [phd]","author":"Watson","year":"2013"},{"key":"10.1016\/j.semarthrit.2024.152507_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.622225","article-title":"The use of glucocorticoids in lupus nephritis: new pathways for an old drug","volume":"8","author":"Mej\u00eda-Vilet","year":"2021","journal-title":"Front Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152507_bib0026","first-page":"1570","article-title":"Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality","volume":"33","author":"Becker-Merok","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152507_bib0027","doi-asserted-by":"crossref","first-page":"8310","DOI":"10.1038\/srep08310","article-title":"Ranking the impact of human health disorders on gut metabolism: systemic lupus erythematosus and obesity as study cases","volume":"5","author":"Rojo","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152507_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000446","article-title":"Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre","volume":"8","author":"Hill","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152507_bib0029","first-page":"824","article-title":"Adjusted mean systemic lupus erythematosus disease activity index-2K is a predictor of outcome in SLE","volume":"32","author":"Iba\u00f1ez","year":"2005","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152507_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000066","article-title":"Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort","volume":"2","author":"Al Sawah","year":"2015","journal-title":"Lupus Sci Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152507_bib0031","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clinthera.2013.03.001","article-title":"Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus","volume":"35","author":"Shah","year":"2013","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.semarthrit.2024.152507_bib0032","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/0961203314532699","article-title":"Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel","volume":"23","author":"Petri","year":"2014","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152507_bib0033","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/rheumatology\/ket322","article-title":"Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study","volume":"53","author":"In\u00eas","year":"2014","journal-title":"Rheumatol Oxf Engl"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152507_bib0034","article-title":"Predicting lupus flares: epidemiological and disease related risk factors","volume":"17","author":"So","year":"2021","journal-title":"Expert Rev Clin Immunol [Internet]"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152507_bib0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13075-017-1442-6","article-title":"Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review","volume":"19","author":"Gensous","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2024.152507_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102615","article-title":"Clinical disease activity and flare in SLE: current concepts and novel biomarkers","volume":"119","author":"Thanou","year":"2021","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152507_bib0037","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152507_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000590","article-title":"Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152507_bib0039","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3899\/jrheum.170645","article-title":"More consistent antimalarial intake in first 5 years of disease is associated with better prognosis in patients with systemic lupus erythematosus","volume":"45","author":"Pakchotanon","year":"2018","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152507_bib0040","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/1744666X.2018.1538789","article-title":"Mortality in systemic lupus erythematosus: causes, predictors and interventions","volume":"14","author":"Ocampo-Piraquive","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152507_bib0041","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/rheumatology\/keg481","article-title":"Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage","volume":"43","author":"Alarc\u00f3n","year":"2004","journal-title":"Rheumatol Oxf Engl"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152507_bib0042","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/0961203308093829","article-title":"Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study","volume":"17","author":"Cardoso","year":"2008","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152507_bib0043","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1191\/096120301670679959","article-title":"Early damage as measured by the SLICC\/ACR damage index is a predictor of mortality in systemic lupus erythematosus","volume":"10","author":"Rahman","year":"2001","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.semarthrit.2024.152507_bib0044","first-page":"1398","article-title":"High predictive value of the systemic lupus international collaborating clinics\/American college of rheumatology damage index for survival in systemic lupus erythematosus","volume":"29","author":"Nived","year":"2002","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152507_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031850","article-title":"Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"10","author":"Murimi-Worstell","year":"2020","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152507_bib0046","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.3899\/jrheum.080214","article-title":"Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus","volume":"35","author":"Urowitz","year":"2008","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152507_bib0047","first-page":"1892","article-title":"Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity","volume":"27","author":"Cook","year":"2000","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152507_bib0048","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0961203314567753","article-title":"Lupus in Latin-American patients: lessons from the GLADEL cohort","volume":"24","author":"Pons-Estel","year":"2015","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152507_bib0049","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40537-018-0143-6","article-title":"Step away from stepwise","volume":"5","author":"Smith","year":"2018","journal-title":"J Big Data"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:14:19Z","timestamp":1726618459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224001471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":49,"alternative-id":["S0049017224001471"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152507","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling long-term outcomes for patients with systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152507"}}